US FDA approves expanded label for Astellas’ Izervay for the treatment of geographic atrophy: Tokyo Friday, February 14, 2025, 09:00 Hrs [IST] Astellas Pharma Inc., a global lif ...
This review describes clinical features, diagnosis and role of various antifungal agents in FE and the management and outcome of species-specific fungal endophthalmitis. Voriconazole Triazole ...
The updated label allows physicians to prescribe Izervay without a limitation on duration for patients with geographic ...
Susvimo Important Safety Information WARNING: ENDOPHTHALMITIS The SUSVIMO implant has been associated with an up to 3-fold ...
Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of ...
IZERVAY dosing approved beyond 12 months TOKYO, Feb. 12, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today ...
However, one of the serious complications that can arise after this surgery is postoperative endophthalmitis, an infection that can lead to vision loss. Recent research has focused on ...
PRISM evaluates 4D-150, a potential backbone therapy designed to provide multi-year sustained delivery of anti-VEGF ...
D Molecular Therapeutics reported 52-week Phase 2b data for 4D-150 in wet AMD, showing sustained visual acuity improvements.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback